

KFIN/CERT13(3)/SEP/2023

Date : October 06, 2023

Mr. Ajay Nadkarni  
M/s. GlaxoSmithKline Pharmaceuticals Limited  
Dr. Annie Besant Road  
Worli, Mumbai-400025.

Sub : Investor Grievance Certificate for the quarter ended September 30, 2023.

Dear Sir,

With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended September 30, 2023.

Description of Complaint	Opening Balance as on 01.07.2023	Received during the Period 01.07.2023 to 30.09.2023	Attended/Resolved during the Period 01.07.2023 to 30.09.2023	Pending as on 30.09.2023
Non-receipt of Dividend	NIL	07	07	NIL
Non-receipt of Annual reports	NIL	NIL	NIL	NIL
Non receipt of shares	NIL	01	01	NIL
SEBI	NIL	01	01	NIL
Stock Exchange	NIL	18	17	01
Total	NIL	27	26	01

This is for your information and record.

Thanking you,

Yours faithfully  
For KFin Technologies Limited



Rajitha Cholleti  
Dy. Vice President